What is the classification and pathology of Nephrotic syndrome?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 5, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Classification and Pathology of Nephrotic Syndrome

Definition and Diagnostic Criteria

Nephrotic syndrome is defined by heavy proteinuria (≥3.5 g/day in adults; ≥1.0 g/m²/day in children), hypoalbuminemia (<3.0 g/dL in adults; <2.5 g/dL in children), and edema, often accompanied by hyperlipidemia. 1, 2

  • Nephrotic-range proteinuria can be confirmed with urine protein:creatinine ratio (PCR) >300-350 mg/mmol 3
  • Patients typically present with periorbital edema (most noticeable in the morning) or dependent pitting edema (later in the day) 3

Classification Systems

Primary (Idiopathic) Nephrotic Syndrome

The classification of nephrotic syndrome divides cases into primary (idiopathic) and secondary forms, with primary cases representing the majority and requiring histopathologic subclassification. 1, 4

Minimal Change Disease (MCD)

  • Characterized by normal-appearing glomeruli on light microscopy but diffuse podocyte foot process effacement on electron microscopy 2
  • Most common cause in children and accounts for the majority of idiopathic nephrotic syndrome 5, 6
  • Typically presents with selective proteinuria, absence of hematuria, and excellent response to steroids 5
  • Long-term kidney survival is excellent in patients who respond to glucocorticoids 1

Focal Segmental Glomerulosclerosis (FSGS)

FSGS requires a novel four-category classification system that fundamentally changes diagnostic and treatment approaches: 1

  1. Primary FSGS: Immunologically mediated, responsive to immunosuppression, characterized by proteinuria >3.5 g/day, serum albumin <3.0 g/dL, and diffuse podocyte foot-process effacement 1

  2. Genetic FSGS: Includes familial, syndromic, and sporadic forms with disease-causing variants in type IV collagen or podocyte genes (found in 11-24% of steroid-resistant cases) 1

  3. Secondary FSGS: Mediated by viral injury, medication-related injury, or adaptive changes (including reduced nephron number from prematurity) 1

  4. FSGS of Undetermined Cause (FSGS-UC): Segmental foot process effacement with proteinuria but without nephrotic syndrome features or evidence of secondary causes 1, 2

  • Workup for secondary causes should occur in patients with non-nephrotic-range proteinuria (<3.5 g/day) or with nephrotic-range proteinuria but albumin >3.0 g/dL 1

Membranous Nephropathy

  • Most common cause of nephrotic syndrome in white adults 3, 4
  • Has unequivocal proof of autoimmune mechanism with pathogenic autoantibodies targeting podocyte antigens 2

Secondary Nephrotic Syndrome

Secondary causes must be systematically excluded through patient history and targeted diagnostic studies: 4

  • Diabetic nephropathy (most common multisystem disease causing nephrotic syndrome) 3
  • Systemic lupus erythematosus 4
  • Medication adverse effects 4
  • Infections (hepatitis C, HIV) 1
  • Amyloidosis 3

Congenital/Genetic Forms

  • Caused by genetic defects in podocytes with common mutations including NPHS1, NPHS2, WT1, and PLCE1 2
  • Includes congenital nephrotic syndrome of Finnish type and infantile mesangial sclerosis 5

Pathophysiology

Molecular Mechanisms

The primary pathophysiological mechanism involves increased glomerular permeability to proteins due to podocyte dysfunction. 2

  • A T-cell-driven circulating "glomerular permeability factor" interferes with glomerular permselectivity to albumin in MCD and FSGS 2, 6
  • Loss of albumin leads to decreased oncotic pressure, causing fluid shift from intravascular to interstitial spaces, resulting in edema 2
  • Hyperlipidemia occurs as a compensatory mechanism for plasma protein loss 2

Pattern-Based Pathologic Classification

The Mayo Clinic/Renal Pathology Society consensus provides a standardized reporting format: 1

  • Primary diagnosis: Specific glomerular disease entity
  • Pattern of injury: Descriptive pattern (e.g., membranoproliferative, necrotizing and crescentic, mesangial proliferative) 1
  • Score/grade: Disease-specific classification systems (e.g., Oxford classification for IgA nephropathy, ISN/RPS for lupus) 1
  • Additional features: Global glomerulosclerosis percentage, tubular atrophy, interstitial fibrosis, vascular changes 1

Clinical Implications and Prognosis

Risk Stratification

Patients with nephrotic-range proteinuria >3.8 g/day have a 35% risk of end-stage renal disease within 2 years. 2

  • Remission of proteinuria is the most significant predictor of renal survival in FSGS 2
  • Steroid-responsiveness is of greater prognostic value than renal histology 6

Complications

Nephrotic syndrome carries significant thrombotic risk with 29% incidence of renal vein thrombosis and 17-28% incidence of pulmonary embolism due to loss of anticoagulant proteins. 2

  • Increased susceptibility to infections due to loss of immunoglobulins and complement factors 2
  • Acute kidney injury can occur as a complication 4

Diagnostic Algorithm

When to Perform Renal Biopsy

Renal biopsy should be performed in two specific circumstances: 5

  1. When clinical symptoms suggest diffuse glomerular lesions (acute nephritic onset, moderate nephrotic syndrome, macroscopic hematuria, marked hypertension/renal insufficiency, poorly selective proteinuria, decreased plasma C3 levels) 5

  2. When steroid resistance has been demonstrated 5

  • In children up to 8 years with typical steroid-sensitive features, biopsy may be deferred as MCNS is most common 5
  • Adults with nephrotic syndrome require biopsy confirmation as FSGS and membranous nephropathy are more common 1

Genetic Testing Indications

Genetic testing should be performed in: 1

  • Patients with familial kidney disease or syndromic features 1
  • Steroid-resistant FSGS cases 1
  • Early-onset cases or those with family history 2

Clinical utility of genetic testing includes: 1

  • Sparing patients from potentially toxic immunosuppression (genetic FSGS much less likely to respond) 1
  • Predicting lower risk of disease recurrence after kidney transplantation 1
  • Guiding enrollment in clinical trials for novel molecular therapies 1
  • Identifying at-risk family members for early diagnosis and treatment 1

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Guideline

Nephrotic and Nephritic Syndrome Mechanisms and Treatment

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Research

Diagnosis and Management of Nephrotic Syndrome in Adults.

American family physician, 2016

Research

Nephrotic syndrome in childhood.

Lancet (London, England), 2003

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.